Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer
- PMID: 16336750
Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer
Comment on
-
Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S81-8. doi: 10.3816/ccc.2005.s.011. Clin Colorectal Cancer. 2005. PMID: 16336753 Review.
-
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S89-97. doi: 10.3816/ccc.2005.s.012. Clin Colorectal Cancer. 2005. PMID: 16336754 Review.
Similar articles
-
Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.Oncology (Williston Park). 2007 Jul;21(8):964-70; discussion 970, 974, 976-7. Oncology (Williston Park). 2007. PMID: 17715697 Review.
-
K-Ras mutations are changing practice in advanced colorectal cancer.J Natl Cancer Inst. 2008 Dec 3;100(23):1667-9. doi: 10.1093/jnci/djn429. Epub 2008 Nov 25. J Natl Cancer Inst. 2008. PMID: 19033564 No abstract available.
-
Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.Pharmacotherapy. 2008 Nov;28(11 Pt 2):31S-41S. doi: 10.1592/phco.28.11-supp.31S. Pharmacotherapy. 2008. PMID: 18980550 Review.
-
Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?Expert Rev Anticancer Ther. 2008 Sep;8(9):1471-80. doi: 10.1586/14737140.8.9.1471. Expert Rev Anticancer Ther. 2008. PMID: 18759698 Review.
-
Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S74-84. J Natl Compr Canc Netw. 2004. PMID: 19780248 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials